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Pharmacokinetics of vancomycin in adults on ECMO 561Conclusion: Vancomycin clearance in patients receiving ECMO with a roller pump was signifi-
cantly lower than that in the matched cohort. Vancomycin PK parameters in patients on ECMO
with a centrifugal pump were comparable to those in the matched control group.
Copyright ª 2015, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Extracorporeal membrane oxygenation (ECMO) was initially
used for neonates with respiratory failure,1 and its use has
expanded to cardiac or respiratory failure in adults.2 Blood
stream infection was the most common infection acquired
during ECMO therapy.3 With increased nosocomial blood-
stream infections by methicillin-resistant Staphylococcus
aureus (MRSA),4 especially in this patient population,5
vancomycin is frequently used to prevent or treat MRSA
infections in patients receiving ECMO in our medical center.
ECMO can be viewed as an artificial heart and lung for
respiratory and circulatory support, and can be used for a
longer period than traditional cardiopulmonary bypass. Its
clinical indications include cardiogenic shock, acute respi-
ratory distress syndrome, organ donation, transplantation,
and short-term bridge of operation. ECMO is composed of a
blood pump, an oxygenator, a heater, and many other
components including a monitor. ECMO circuits probably
represent another pharmacokinetic (PK) compartment
because they can sequester a significant amount of drug,
and therefore increase the volume of distribution (Vd).
6
There are various methods such as venoarterial (VA) and
venovenous (VV) modes to cannulate ECMO. VA ECMO is
achieved by drawing blood from a vein, such as the jugular
vein, passing the blood through the oxygenator, and pump-
ing the blood into the aortic arch. The VV mode is similar to
the VA mode, except that the blood is pumped back into a
different vein. Because the VA mode lacks pulsatility, renal
function is transiently altered.7 Altered renal function is also
found in the VV mode.8 Dagan et al9 found that drug dispo-
sition was altered because the oxygenator could sequester
many medications such as vancomycin. In summary, ECMO
may alter PK by decreasing drug elimination, increasing the
Vd, and sequestering drugs in the ECMO circuits.
6
In patients with normal renal function, the reported
vancomycin Vd, clearance (CL), and half-life (t1/2) are
respectively 0.5e1 L/kg, 0.9e1.45 mL/min/kg, and 5e9
hours.10e14 However, there is limited data on vancomycin
PK in adult patients receiving ECMO. Previous studies on the
PK of vancomycin in patients receiving ECMO are mostly
limited to neonates, and the results are conflicting. Some
studies reported a lower vancomycin CL, a larger Vd, and a
longer t1/2,
15e17 while other studies reported that ECMO did
not affect the vancomycin PK.18
Despite the increasing use of vancomycin in adult pa-
tients receiving ECMO,19 there is only one noncontrolled
study that evaluated the effect of ECMO on vancomycin PK
in adults.17 The objective of this matched-cohort study was
to determine the influence of ECMO on the PK of vanco-
mycin in adults. Determination of an appropriate dosage
regimen was also intended for these patients.Methods
Patient eligibility
This prospective, matched-cohort study was approved by
the research ethics committee of the National Taiwan
University Hospital, Taipei, Taiwan. The patients on ECMO
who received vancomycin treatment, were at least 18 years
old were eligible for the study. The patients who used
continuous renal replacement therapy, hemodialysis, plas-
mapheresis, had acute kidney injury [an increase in serum
creatinine (SCr) of  0.3 mg/dL in 24 hours or a reduction in
urine output with an output of < 0.5 mL/kg/h for > 6
hours], or suffered from severe burns over 30e40% of the
body surface area were excluded from this study. These
patients were recruited after informed consent was ob-
tained from them or their representatives.
For each patient in the ECMO group, a control patient
was matched by age ( 60 years or < 60 years), gender, and
creatinine clearance (CLCr, mL/min/1.73 m
2) in intensive
care units. The CLCr was matched by a difference of <
20 mL/min/1.73 m2 or a CLCr in the identical range group (>
90 mL/min/1.73 m2, 60e89 mL/min/1.73 m2, 30e59 mL/
min/1.73 m2, and < 30 mL/min/1.73 m2). The CLCr was
estimated using the Cockcroft and Gault method (CG
method). If a patient’s SCr was < 0.8 mg/dL, it will be
replaced by 0.8 mg/dL to avoid overestimation of the pa-
tient’s renal function. For obese patients [(true body
weighteideal body weight)/ideal body weight > 30%], the
Salazar-Corcoran equation was used to estimate the CLCr.
20
The CLCr was normalized to a body surface area of 1.73 m
2.
From December 2005 to December 2006, each group
recruited 12 patients.ECMO apparatus
The ECMO system was predominantly composed of a blood
pump, a membrane oxygenator, a heater (ECMO-TEMP Unit,
Zimmer Patient Care Division, Dover, OH, USA), arterial and
venous cannulas, pump tubing, and other monitors. Two
types of blood pumps were used for the ECMO group. One
blood pump is the centrifugal pump (Biomedicus Pump
Console 550, Medtronic Bio-medicus Inc., Eden Prairie, MN,
USA) connected with a hollow fiber microporous membrane
oxygenator (CBIV97R, Medtronic Inc., Anaheim, CA, USA),
and the other type was a roller pump (Precision blood
pump, COBE Cardiovascular, Inc., Arvada, CO, USA) con-
nected with a silicone membrane oxygenator (Avecor I4500,
Medtronic Inc., Anaheim, CA, USA). The priming fluid was
850 mL of normal saline for the centrifugal pump and
1500 mL of normal saline plus 500 mL of packed red blood
562 C.-C. Wu et al.cells (pRBC, 80% hematocrit) for the roller pump. The se-
lection of a blood pump was determined by the physicians.
Clinical protocol
The initial loading dose of vancomycin hydrochloride
(Vancocin, Eli Lilly Japan K.K, Seishin Laboratories, Kobe,
Japan) for the prevention or treatment of MRSA infections
was 15e25 mg/kg. The maintenance dose was determined
using the PK dosing method [with an empirical Vd Z 0.7 L/
kg, CL Z 0.695*CLCr (mL/min/kg) þ 0.05, and KZ CL/Vd]
to achieve trough levels within 10e20 mg/L.21 Vancomycin
was infused through a central venous catheter over at least
1 hour, and serial blood samples (5e9) were drawn from the
radial or brachial artery line according to the dosing in-
tervals, which could be every 6 hours, 8 hours, 12 hours, 24
hours, or 48 hours. The sampling times were 0.5 hours, 1
hour, 2 hours, 3 hours, 7 hours, 11 hours, 23 hours, 35 hours,
and 47 hours postinfusion. If the dosing interval was 6 hours
or 8 hours, an extra sample was drawn at 5 hours
postinfusion.
Vancomycin assay method
The drug concentrations in serum were measured using a
fluorescence polarization immunoassay (AxSYM system,
Abbott Laboratories, Abbott Park, IL, USA). The sensitivity
of the assay (the lowest measurable level) was 2 mg/L, and
the coefficients of variation at 7.0 mg/L, 35.0 mg/L, and
75.0 mg/L were all < 5%.
Data collection
Demographic and clinical data were recorded for every
patient and included age, sex, height, indications for
ECMO, type of blood pump, mode of ECMO, vancomycin
maintenance dose, and dosing interval. The body weight,
SCr, total bilirubin, aspartate aminotransferase, and alanine
aminotransferase on the sampling day were recorded.
Noncompartmental PK analysis
The PK parameters were analyzed using WinNonlin (Win-
Nonlin professional version 4.1, Pharsight Corporation, St.
Louis, MO, USA). The serum vancomycin concentrations for
all the patients were fitted to a noncompartment inter-
mittent IV infusion model at steady state. The postinfusion
log vancomycin concentration in serum time profiles was
analyzed with the linear least-squares regression method to
estimate the elimination rate constant (k). The t1/2, CL,
and volume of distribution at steady state (Vss) were esti-
mated using the following equations:
t1/2 Z 0.693/k;
CL Z dose/AUC0t;
and
Vss Z CL  MRTinf;where AUC0-t is the area under the serum concentration
versus time curve over the dosing interval calculated by the
linear trapezoidal rule. The MRTinf is the infinite mean
residence time.
After acquiring the individual PK parameters, the prin-
ciples of superposition22 to predict the vancomycin serum
concentrations of each patient was used. The predicted
and true concentrations were used to create individual
residual plots to assess the appropriateness for setting the
steady state. The CL and Vss were adjusted to achieve an
appropriate steady state setting if needed.
Statistical analysis
The demographic and PK data were compared with a two-
tailed paired t test for continuous data, except PK data
between the centrifugal pump group and the roller pump
group, which were compared with an independent t test.
The Chi-square test was used for binomial data. Simple
linear regression analysis was used to test for significant
relationships between the PK parameters (CL, Vss, t1/2) and
the CLCr. A p value  0.05 was considered statistically sig-
nificant. The statistical analysis was performed by SPSS 11.5
(SPSS Inc., Chicago, IL, USA).
Population pharmacokinetic analysis
The population PK analysis was performed using NONMEM
(Version VI, NONMEM Project Group, University of Califor-
nia, San Francisco, CA, USA) with G77 FORTRAN compiler.
NONMEM runs were executed using Wings for NONMEM
(WFN; Version 6.1, University of Auckland, Auckland, New
Zealand). Wings for NONMEM was also used for model
validation using bootstrap resampling. One-, two-, and
three-compartment models with first order elimination
were fitted to the data using the first-order conditional
method of estimation with interaction. Interindividual
variability in the PK parameters was modeled with the use
of an exponential error model as follows:
Pj Z qx EXP(h);
where Pj is the predicted PK parameter value for the j
th
patient. q is the typical value of PK parameter in NONMEM.
h (ETA) is the random variable, normally distributed with
mean equal to 0 and a variance equal to u2. The following
residual error models to describe residual variability of the
population PK model were tested:
Proportional error model: CijZ C^ij x (1 þ ε1ij)
Additive error model: CijZ C^ij þ ε2ij
Combined model (additive and proportional component):
CijZ C^ij x (1 þ ε1ij) þ ε2ij
where Cij is the j
th measured observation (plasma concen-
tration) in individual i. C^ij is the j
th model predicted value
(plasma concentration) in individual i. ε1ij is the propor-
tional component of the residual, residual error for the jth
measurement in individual i, with a mean of 0 and a vari-
ance of s1
2. ε2ij is the additive component of the residual,
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During the model-building process, the minimum value
of the NONMEM objective function (OFV; -2 times the log of
the likelihood of the data) was used to discriminate be-
tween different models: the better the model fit the data,
the lower the OFV. In terms of OFV, differences were
assumed to have a c2 distribution for nested models. OFV
reductions (from basic model to nested model) of 3.83
points, 6.63 points, and 10.83 points correspond to
improved fits at p < 0.05, p < 0.01, and p < 0.001 levels.
The following covariates were tested for their potential
influence on PK parameters: age, sex, body weight, CLCr,
albumin, type of blood pump, and mode of ECMO. The full
and final model development including the covariate
testing was done using the method of “forward inclusion
and stepwise backward elimination”. In this study, a
decrease in the OFV > 3.84 points (i.e., p < 0.05) and 10.8
points (i.e., p < 0.001) were the criteria used in the for-
ward inclusion and backward exclusion steps, respectively.
In addition, the goodness-of-fit of the different popula-
tion models for vancomycin plasma concentrations was
assessed by visual inspection of the following diagnostic
plots: (1) observed concentrations versus individual pre-
dicted concentrations; (2) observed concentrations versusTable 1 Demographic data in the ECMO group and matched co
Patient no.a Age (y) Sexb Height (cm) Weight (kg)
E1 73 M 168 69
E2 18 M 176 85.8
E3 36 M 173 104.9c
E4 42 M 176 68
E5 32 M 156 76.4c
E6 40 F 161 60.5
E7 54 F 160 64.7c
E8 44 M 150 52.6
E9 67 F 155 43.1
E10 45 F 148 55.9
E11 68 F 150 51.4
Mean (SD) 47.18 (16.85) 161.18 (10.52) 66.57 (17.53)
C1 72 M 170 80.4
C2 51 M 162 61.7
C3 39 M 170 73.6
C4 18 M 168 69.8
C5 35 M 170 68.3
C6 38 F 171 63.6
C7 54 F 160 65.3c
C8 38 M 150 53.9
C9 67 F 160 46.8
C10 55 F 148 42.2
C11 72 F 165 79.2c
Mean (SD) 49.00 (17.16) 163.10 (8.08) 64.07 (12.34)
a E Z ECMO group; C Z matched cohort.
b M Z male; F Z female.
c obese.
d CLCrZ creatinine clearance; SCr Z serum creatinine.
e C Z centrifugal pump; R Z roller pump.
f VA Z venoarterial; VV Z venovenous; VVA Z hybrid venoarterialpredicted concentrations; (3) weighted residuals versus
predicted concentrations; and (4) weighted residuals versus
time. The stability of the final model was evaluated by
bootstrapping method. The median parameter estimates
obtained from 200 bootstrap replicates were compared
with estimates from original dataset.
By using the final population PK model, a simulation was
performed for a 50-year-old patient with a body weight of
70 kg and CLCr of 80 mL/min/1.73 m
2. Vancomycin was
administered at doses of 500 mg, 750 mg, and 1000 mg as a 1
hour infusion (dosing interval of 6 hours, 8 hours, or 12
hours). The concentrationetime profiles of vancomycin
were simulated using 1000 replicates of the subject based on
the fixed and random effect parameters of the final model,
and the median values were computed for the comparison.Results
Twenty-four patients were included in this study originally.
However, one patient in the ECMO group was excluded
because of acute kidney injury, and her matched control
was therefore excluded from the final analysis. Twenty-two
patients were finally enrolled in the two study groups. There
were no significant differences between the two groups inntrol group.
SCr (mg/dL)
d CLCr (mL/min/
1.73 m2)d
Albumin (g/dL) ECMO
pumpe
Modef
1.3 42.78 3.16 C VA
1.7 52.27 3.76 C VA
0.7 61.61 2.23 C VA
1.7 93.23 3.04 C VA
0.8 95.29 2.99 C VA
1.1 96.79 2.94 C VV
0.3 95.53 2.84 C VVA
0.6 106.78 2.58 R VV
2.3 68.26 3.01 R VA
0.7 27.97 2.96 R VV
0.7 69.57 2.81 R VA
1.08 (0.6) 74.10 (25.42) 2.94 (0.37)
0.9 59.59 2.63
1.1 67.37 3.53
0.6 50.97 2.81
1.6 145.96 3.2
0.3 127.65 3.59
0.7 96.65 3.33
0.6 95.57 3.42
0.4 116.53 3.1
1.3 71.57 2.78
0.7 40.35 3.31
1 56.30 2.69
0.83 (0.39) 84.41 (34.47) 3.12 (0.34)
and venovenous.
564 C.-C. Wu et al.the demographic data such as age, height, weight, SCr, CLCr,
and albumin (Table 1). The diagnoses of the patients in the
ECMO group included acute respiratory distress syndrome,
heart failure, cardiogenic shock, myocarditis, and coronary
artery syndrome. The diagnoses of the patients in the con-
trol group included trauma, valvular heart disease, cancer,
infective endocarditis, septic shock, myocarditis, intrace-
rebral hemorrhage, and dissecting aortic aneurysm. In the
ECMO group, a centrifugal pump was used for seven pa-
tients, and a roller pump was used for four patients. The VA,
VV, and hybrid VV/VA modes were used in seven patients,
three patients, and one patient, respectively. There were
three obese patients and two obese patients in the ECMO
and the control group, respectively.
Noncompartmental PK analysis
Only two patients had their samples drawn after the third
dose. Samples from the other patients were drawn after atTable 2 Noncompartmental pharmacokinetic data in the
ECMO group and matched control group.
ECMO K
(h1)
CL (mL/
min/kg)
Vss
(L/kg)
Control K
(h1)
CL (mL/
min/kg)
Vss
(L/kg)
1 0.070 0.92 0.79 1 0.088 1.06 0.72
2 0.069 0.72 0.63 2 0.149 1.24 0.50
3 0.065 0.53 0.47 3 0.044 0.35 0.74
4 0.067 2.37 0.82 4 0.029 2.56 0.48
5 0.173 0.85 1.00 5 0.324 2.78 1.04
6 0.051 2.08 0.71 6 0.161 2.63 0.54
7 0.176 2.15 0.79 7 0.293 1.52 0.81
8 0.068 0.83 0.76 8 0.078 0.92 1.24
9 0.025 1.36 1.21 9 0.022 1.52 1.17
10 0.163 0.30 0.73 10 0.112 0.46 1.24
11 0.039 0.84 1.29 11 0.120 0.96 0.48
Mean 0.088 1.18 0.84 0.129 1.45 0.81
(SD) (0.055) (0.71) (0.24) (0.10) (0.86) (0.31)
CLZ clearance; kZ elimination rate constant; VssZ volume of
distribution at steady state.
Table 3 Pharmacokinetic data in the ECMO group stratified by
group.
Centrifugal pump
(n Z 7)
Matched control-C
(n Z 7)
SCr (mg/dL) 1.09  0.52 0.84  0.41
CLCr (mL/min/1.73 m
2) 77.5  22.83 91.96  35.49
k (h1) 0.110  0.057 0.18  0.13
CL (mL/min/kg) 1.37  0.79 1.80  1.00
Vss (L/kg) 0.74  0.17 0.72  0.20
*p < 0.05.
CL Z clearance; CLCr Z creatinine clearance; k Z elimination rate c
steady state.
a Comparison of the pharmacokinetics of the centrifugal pump grou
b Comparison of the pharmacokinetics of the roller pump group wit
c Comparison of the pharmacokinetics of the centrifugal pump grouleast the fourth dose. There were no significant differences
in the PK parameters of the ECMO group and the matched
control; vancomycin CL, 1.18  0.71 mL/min/kg versus
1.45  0.86 mL/min/kg; Vss, 0.84  0.24 L/kg versus
0.81  0.31 L/kg and k, and 0.088  0.055 hour1 versus
0.129  0.100 hour1 (Table 2).
When stratified by the type of blood pump, there were
no significant differences in the SCr and CLCr whether a
centrifugal pump or roller pump was used (Table 3). The
vancomycin CL in the roller pump group was significantly
lower than that in control group (0.83  0.43 mL/min/kg vs.
0.97  0.43 mL/min/kg, p Z 0.002). The elimination rate
constant in the roller pump group was significantly lower
than that in centrifugal pump group (0.049  0.021 hour1
vs. 0.110  0.057 hour1, p Z 0.045).
The CLCr was a predictor of vancomycin CL for the ECMO
group [correlation coefficient (r) Z 0.61, R2 Z 0.37,
p Z 0.045] and the matched control group (r Z 0.78,
R2 Z 0.61, p Z 0.005; Figure 1).
A linear relationship between the CLCr and vancomycin
CL in all 22 patients (vancomycin CLZ 0.019 * CLCr e 0.178,
r Z 0.73, R2 Z 0.53, p < 0.001) was used to establish a
dosage regimen for the critically ill patients; where the unit
for the vancomycin CL is mL/min/kg. After loading with
15 mg/kg, a maintenance dose to achieve an average
steady-state concentration (Cav, ss) of 25 mg/L can be
calculated as follows:
dose (mg/kg/24 h)Z vancomycin CL (L/h/kg)  Cav, ss (mg/
L)  24 (hour).
We substituted vancomycin CL with (0.019 CLCr e 0.178) in
the equation to produce a new equation, i.e.,
maintenance dose (mg/kg/24 h) Z 0.684 * CLCr (mL/min/
1.73 m2) e 6.408.
This equation is only suitable for patients with a CLCr
greater than 20 mL/min/1.73 m2. The t1/2 of vancomycin
was determined by the CLCr by a linear relationship [t1/2
(hour) Z 0.159*CLCr (mL/min/1.73 m2) þ 23.3, r Z 0.59,
R2 Z 0.34)], and a dosing interval close to the t1/2 was
determined (Table 4).the type of blood pump and the respective matched control
Roller pump
(n Z 4)
Matched control-R
(n Z 4)
pa pb pc
1.08  0.82 0.83  0.40 0.09 0.42 0.98
68.15  32.19 71.19  32.80 0.13 0.63 0.63
0.049  0.021 0.066  0.042 0.13 0.53 0.045*
0.83  0.43 0.97  0.43 0.12 0.002* 0.13
1.00  0.29 1.03  0.37 0.86 0.95 0.24
onstant; SCr Z serum creatinine; Vss Z volume of distribution at
p with control (control e C).
h control (control e R).
p with the roller pump group.
Figure 1 Vancomycin clearance versus creatinine clearance.
In the ECMO group: n Z 11, r Z 0.61, R2 Z 0.37, y Z 0.017x
0.086, p Z 0.045. In the control group: n Z 11, r Z 0.78,
R2 Z 0.61, y Z 0.019x e 0.185, p Z 0.005. In all patients:
n Z 22, r Z 0.73, R2 Z 0.53, y Z 0.019x e 0.178, p < 0.001.
CL Z clearance; CLcr Z creatinine clearance.
Table 4 Dosing interval of vancomycin as determined by
creatinine clearance.
CLCr (mL/min/1.73 m
2) t (h) CLCr (mL/min/
1.73 m2)
t1/2 (h)
a
 100 6 120 4.17
110 5.76
100 7.35
80e99 8 90 8.94
80 10.53
40e79 12 70 12.12
60 13.71
50 15.30
40 16.89
20e39 24 30 18.48
20 20.07
CLCr Z creatinine clearance; t Z dosing interval; t1/2 Z half-
life.
a t1/2 (hour) Z 0.159*CLCr (mL/min/1.73 m2) þ 23.3.
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A one-compartment model with first-order elimination was
found to optimally describe the concentration time course
of vancomycin. Exponential and proportional error models
were used to describe the intersubject and residual vari-
ability, respectively. The final population estimates for PK
parameters, such as the vancomycin CL and Vss, are shown
in Table 5. All PK parameters were scaled by body weight
and were estimated with reasonable precision (% relative
standard error < 35%). The interindividual variability for
vancomycin CL and Vss were 38.3% and 21.2%, respectively.
The residual variability of the model was 16.3%. In the final
covariate model, CLcr were identified as a significant co-
variate for vancomycin CL. Age was also found to be asignificant covariate for Vss. The final model can be repre-
sented by the following equations:
Vancomycin CL (mL/min/kg) Z 0.0145  CLcr
Vss (L/kg) Z 0.83  (age/47.9)0.44
The diagnostic plots of the final model are given
(Figure 2). The individual- and population-predicted van-
comycin concentrations show good agreement with
the observed vancomycin concentrations (Figures 2A and
2B), demonstrating that the model adequately described
the data. The plots of weighted residual versus
the population-predicted vancomycin concentrations
(Figure 2C) or time (Figure 2D) do not show any obvious
trend. From 200 bootstrap runs, all the runs had a suc-
cessful minimization and were included in the bootstrap
analysis. All model estimates lie within the bootstrapped
95% confidence interval range. The median parameter
estimates from the bootstrap datasets were close to those
from the original dataset, indicating the population PK
model was stable.
The concentrationetime profiles of vancomycin, after
multiple doses of 500 mg, 750 mg, and 1000 mg as a 1 hour
infusion (dosing interval of 6 hours, 8 hours, or 12 hours),
was simulated with the final PK model (Figure 3). The
current vancomycin therapeutic guidelines recommend
targeting vancomycin trough concentrations of 10e20 mg/L
for patients with complicated infections. In accordance to
the above mentioned guide, a dosing regimen of 500 mg
repeated every 6 hours, 750 mg repeated every 8 hours, and
1000 mg repeated every 12 hours seems to be optimal for a
50-year-old, 70 kg patient with a CLCr of 80 mL/min/
1.73 m2.
Discussion
This study is the first prospective, matched cohort study to
explore the effect of ECMO on the PK of vancomycin in
adults. To the best of our knowledge, it is also the first
Table 5 Population pharmacokinetic parameters of final model.
Parameters (unit) Estimate (%RSE) 200 Bootstrap replicates
Median (2.5th, 97.5th percentile)
Fixed parameters
CL (mL/min/kg) Z q1  CLcr (mL/min/1.73 m2)
q1 0.0145 (8.4) 0.0145 (0.0127, 0.0167)
V ðL=kgÞZq2  ðAge ðyearsÞ=47:9Þq3
q2 0.83 (7.6) 0.83 (0.72, 0.97)
q3 0.44 (34.9) 0.43 (0.14, 0.83)
Interindividual variability
uCL (%) 38.3 (23.3) 37.4 (27.2, 45.0)
uV1 (%) 21.2 (33.2) 19.8 (5.0, 26.3)
Residual variability
s (%) 16.3 (23.8) 16.3 (12.6, 19.4)
u Z intersubject variability; s Z residual variability.
566 C.-C. Wu et al.study that enrolled patients on ECMO with a centrifugal
pump. Vancomycin PK may be altered during ECMO in adult
patients due to multiple reasons including priming volume,
transfusion and hemodilution, decreasing renal function,
and sequestering drugs in the ECMO circuit.6 The results in
our study did not show ECMO to be a significant covariate to
impact vancomycin PK when a centrifugal pump was used.
CLCr and age were two significant covariates of vancomycin
CL and Vss, respectively. However, vancomycin CL was
significantly lower than that in the matched cohort when
roller pump was used. The elimination rate constant of
vancomycin was significantly lower in the roller pump group
than that in the centrifugal pump group.
Prior to our study, there has been only one uncontrolled
study conducted by Mulla and Pooboni,17 which enrolled 18
adult patients and used a population PK method to estimate
the vancomycin PK parameters in adults who received ECMO
with a roller pump. The study revealed a much lower van-
comycin CL but a similar Vss when compared with our study
(Table 6). Although it concluded that there was a decreased
vancomycin CL and increased Vss in patients receiving
ECMO, the lack of a control groups limits accurate inter-
pretation of their findings. The kinetic changes might have
been due to the patients’ critical condition. All the other
studies focused on neonates and are difficult to compare
with our study. Hoie et al18 conducted a prospective study
of six neonates, and Mulla and Pooboni17 also enrolled ne-
onates and children. The PK parameters of vancomycin
found in these two studies were similar to those found in
studies of other neonates not undergoing ECMO.23,24 Buck16
conducted a retrospective controlled study of 15 neonates
and found that only the t1/2 was significantly longer in ne-
onates receiving ECMO (Table 6). The study by Amaker
et al15 was the only study to reveal a large change in the PK
parameters in neonates. This may be explained by higher
percentage of extracellular fluid expansion in neonates
using ECMO. The addition of priming fluid expanded the
extracellular fluid by 36% for a 4-kg neonate and by 6e15%
for a 70-kg adult. Because the percentage extracellular
fluid expansion is lower in adult, there were no significant
difference in k, Vss, and CL in our study (Table 6).
Sequestration of drugs in the ECMO circuit was
considered as a factor in changing the drug disposition.9
However, the intergroup difference of the Vss was only0.03 L/kg in our study. This difference was most likely
caused by the priming fluid instead of the sequestration
of the drugs in the circuit. Shekar et al25 demonstrated
that there was no significant circuit loss of vancomycin. In
our study, ECMO was used for many days before the blood
sampling, and many drugs, such as albumin, were used
concurrently, which might decrease the binding sites
on the ECMO circuit and minimize the effect of
sequestration.
There was a trend toward a lower vancomycin CL and a
longer t1/2 in patients receiving ECMO in this and other
studies. Vancomycin is eliminated predominantly by
renal excretion. The nonpulsatile blood flow of the
ECMO circuit could increase the sympathetic tone and
result in decreased renal perfusion and urine output, which
could decrease the elimination of vancomycin and lead to a
lower vancomycin CL and a longer t1/2.
26 The patients
receiving ECMO with a roller pump in our hospital were
often more critically ill than those on a centrifugal pump,
and the renal function in the roller pump group was worse
than that in the centrifugal pump group. This can be the
cause of a significantly lower k in the roller pump group. In
addition, although not statistically significant, the Vss was
larger and the vancomycin CL was lower in the roller pump
group. A silicone membrane oxygenator may sequester
more drugs than a hollow fiber microporous membrane
oxygenator.27 This is a possible cause of larger Vss in the
roller pump group. There is an increasing tendency to use a
centrifugal pump that offers several potential benefits over
a roller pump, which includes a smaller circuit size to lower
circuit prime volumes and a smaller surface area for
bloodeprosthetic surface interaction to minimize activa-
tion of inflammatory factors.28 These advantages may also
cause PK differences between the two different pump
groups. To the best of our knowledge, only our study had
enrolled patients receiving centrifugal pump. However, it
also implied this study consisted of heterogeneous groups
including two different pumps used and three types of
cannulation method.
The trough serum concentration is the most accurate
and practical method for monitoring vancomycin efficacy
and should be maintained at 10e20 mg/L to prevent
resistance and maintain efficacy.29 However, in our study,
only 27% (3 in 11) patients in the ECMO group achieved this
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apeutic and 18.2% exceeded 20 mg/L in the ECMO group.
Similar results were seen in the matched control group.
Even though a short dosing interval such as every 6 hours
was used, > 50% was subtherapeutic. Many dosing nomo-
grams were used empirically to give the vancomycin dose;
however, critically ill patients were not enrolled in these
studies.10,11,30 This may explain the high percentage of
inadequate trough level when using these nomograms.
Therefore, a specific dosage regimen for patients on ECMO
is required.
Based on the dosing simulation with population PK, in a
patient with a CLCr of 80 mL/min/1.73 m
2, vancomycin
dose of 1000 mg every 12 hours could achieve target
trough level (Figure 3). However, not every critically ill
patient has the same renal function. Therefore, a dosing
equation:
maintenance dose (mg/kg/24 hours) Z 0.684 * CLCr (mL/
min/1.73 m2) e 6.408]
was derived in this study for ECMO group and control group
utilizing the correlation between vancomycin CL and CLCr
(r Z 0.73 in all patients). Although this equation is derived
from a critically ill population, close monitoring of the
vancomycin serum concentration is still recommended
because of the moderate correlation. Continuous infusion
of vancomycin is a probable solution to maintain concen-
tration within therapeutic range. However, although
continuous infusion of vancomycin could achieve target
concentration faster and caused less renal toxicity than
intermittent infusion, the overall mortality was not signif-
icantly different.31,32 Further studies are needed to vali-
date the new dosing method and continuous infusion of
vancomycin in patients using ECMO.
There are some limitations to our study. Firstly, the
small population of our study may not have enough power
to detect the true difference between the groups. The
difference in the Vss of vancomycin between the groups was
too small to be clinically significant. Further studies are
needed to prove a meaningful trend of a lower vancomycin
CL in patients receiving ECMO. Secondly, the disease status
was very different between the two groups. The vanco-
mycin PK may be altered by severe diseases through the
effects on renal function. However, this study matched the
CLCr of the two groups to minimize the effect of different
disease status. Although CLCr by measuring 24-hour urine is
a gold standard for renal function assessment, it is not a
routine practice in our intensive care units. The CG method
was used in our study for renal function matching because
of the good linear correlation between CLCr by measuring
24-hour urine and CLCr estimated by CG method
(R2 Z 0.84).33 In addition, when CLCr < 100 mL/min/
1.73 m2, the difference between these two method wasFigure 2 Basic goodness-of-fit plots for the final population
PK model. (A) Observations versus population predictions; (B)
observations versus individual predictions; (C) weighted re-
siduals (WRES) versus population predictions; (D) weighted
residuals (WRES) versus time. Solid and dotted line: the line of
identity and LOESS smoothed fit, respectively.
Figure 3 Simulation of steady state concentrations of vancomycin for the: (A) 6 hour interval repeated dosing regimen; (B) 8 hour
interval repeated dosing regimens; and (C) 12 hour interval repeated dosing regimens at 500 mg (dash line), 750 mg (continuous
line), and 1000 mg (dot line). The shaded area represents the target concentrations of 10e20 mg/L.
568 C.-C. Wu et al.lower than 5. Finally, because the CLCr of all patients was >
20 mL/min/1.73 m2, the dosage regimen derived from this
study can only be applied in patients with a CLCr > 20 mL/
min/1.73 m2. Further studies are needed to confirm the
precision of this dosing equation.Conclusion
In patients receiving ECMO with a roller pump, vancomycin
clearance is significantly lower than that in the matched
group. Vancomycin PK parameters in patients on ECMO with
Table 6 Pharmacokinetic parameters of vancomycin in patients receiving ECMO in different studies.
Study Study population (n) Vss (L/kg) CL (mL/min/kg) t1/2 (h) Pump Priming fluid (mL) Increment
in ECF (%)a
Increment
in plasma (%)apRBC (Hct%) N/S Expanded volume
Amaker et al15 Neonates (12) R 400 NA 120 8.6 34.3
SCr> 1.5 1.22  0.63 0.59  0.15 24.24  13.39
SCr< 1.5 0.99  0.35 0.87  0.14 13.22  4.45
Hoie et al18 Neonates (6) 0.68  0.12 1.10  0.32 7.71  2.61 R 300 NA 120 4.6 34.3
Mulla and Pooboni17 Neonates (15) 0.67  0.15 0.66  0.33 10.40  6.67 R NA NA 500 35.7 142.9
Adults (18) 0.73  0.28 0.66  0.33 8.55  4.64 R NA NA 2200 15.7 62.9
Buck16 Neonates (30) R NA NA NA
ECMO (15) 0.45  0.18 0.65  0.28 8.29  2.23*
Control (15) 0.39  0.12 0.79  0.41 6.53  2.05
Our study Adults (23) R 500 (80) 1500 1600 11.4 45.7
C 0 850 850 6.0 24.3
ECMO (11) 0.84  0.24 1.18  0.71 11.13  9.08
Control (11) 0.81  0.31 1.45  0.86 10.31  9.99
* p < 0.05.
CZ centrifugal pump; ECFZ extracellular fluid; NAZ not available; N/SZ normal saline; PRBCZ pack red blood cells; RZ roller pump; VssZ volume of distribution at steady state.
a Based on a 4 kg neonate and a 70 kg adult. ECF of a neonate (4 kg): 1400 mL, plasma of a neonate: 350 mL. ECF of an adult (70 kg):
4000 mL; plasma of an adult: 3500 mL. Expanded volume Z N/S þ RBC*(1-Hct).
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570 C.-C. Wu et al.a centrifugal pumpwere comparable to those in thematched
cohort. There was a higher risk of under dosing in both the
ECMO and the matched groups, and close monitoring of
serum drug concentration was recommended. Administering
vancomycin as a 24-hour continuous infusion, especially in
patients with higher CLCr, needs further investigation.
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